Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.

Mol Cancer · 2025 · PMC12512572 · PMID 41068915

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

DMFS shown significant enhancement (HR 0.384; p = 0.0154), while OS demonstrated a positive trend, with 2.5-year rates of 96.0% for the combined treatment compared to 90.2% for monotherapy.

also in 11,005 other papers

may be significantno p-value reported

Whole exome sequencing of this patient’s tumor identified missense mutations in the mTOR and FGFR2 genes, which may be significant due to nucleolin’s function in augmenting mTOR pathway activity through AKT1 mRNA translation.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.